Article
RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $12
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $9 to $12.
Comments
- No comments yet. Be the first to comment!